A Patient’s Diagnosis with HER2+ Metastatic Colorectal Cancer

Video

Patient Elle Charnisky shares the symptoms that led to her diagnosis of HER2+ metastatic colorectal cancer, and the online resources she used for education after.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC

Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC

Jason M. Broderick
May 31st 2025
Article

As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Jordyn Sava
May 31st 2025
Article

The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Updated findings from BREAKWATER support encorafenib plus cetuximab and chemotherapy as a new standard of care in BRAF V600E-mutated metastatic CRC.

PFS Improves in BRAF V600E+ CRC With Encorafenib Combo

Chris Ryan
May 30th 2025
Article

Updated findings from BREAKWATER support encorafenib plus cetuximab and chemotherapy as a new standard of care in BRAF V600E-mutated metastatic CRC.

Among patients with rectal cancer who underwent total mesorectal excision following SCRT plus camrelizumab and chemotherapy, the 3-year OS rate was 93.3%.

Neoadjuvant SCRT Combo May Prolong Survival in Advanced Rectal Cancer

Roman Fabbricatore
May 25th 2025
Article

Among patients with rectal cancer who underwent total mesorectal excision following SCRT plus camrelizumab and chemotherapy, the 3-year OS rate was 93.3%.